We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.88B
AUM Growth
-$278M
Cap. Flow
-$105M
Cap. Flow %
-5.61%
Top 10 Hldgs %
47.5%
Holding
84
New
5
Increased
6
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$39.9M
3
PRTA icon
Prothena Corp
PRTA
+$19.3M
4
IMVT icon
Immunovant
IMVT
+$17M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$13.6M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$146M
2
ETNB
89bio
ETNB
+$39.8M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$32.5M
4
CABA icon
Cabaletta Bio
CABA
+$6.97M
5
IRON icon
Disc Medicine
IRON
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
26
Axsome Therapeutics
AXSM
$11.2B
$28M 1.49%
400,000
– –
EXEL icon
27
Exelixis
EXEL
$13.3B
$25.1M 1.34%
1,150,000
– –
ANAB icon
28
AnaptysBio
ANAB
$1.58B
$23.3M 1.24%
1,300,000
– –
SAGE
29
DELISTED
Sage Therapeutics
SAGE
$22.5M 1.2%
1,094,000
– –
VKTX icon
30
Viking Therapeutics
VKTX
$3.7B
$22.1M 1.18%
2,000,000
– –
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.06B
$20.5M 1.09%
600,000
– –
ITOS
32
DELISTED
iTeos Therapeutics
ITOS
$19.8M 1.05%
1,804,058
-350,000
-16% -$4.48M
PMVP icon
33
PMV Pharmaceuticals
PMVP
$59.2M
$19.4M 1.03%
3,163,795
– –
IOVA icon
34
Iovance Biotherapeutics
IOVA
$1.82B
$16.9M 0.9%
3,705,133
– –
PNT
35
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$16.7M 0.89%
2,500,000
– –
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$15.9M 0.85%
1,650,000
– –
RLAY icon
37
Relay Therapeutics
RLAY
$4.1B
$15.3M 0.81%
1,819,132
– –
MDGL icon
38
Madrigal Pharmaceuticals
MDGL
$10.8B
$14.6M 0.78%
100,000
– –
DAWN
39
DELISTED
Day One Biopharmaceuticals
DAWN
$14.6M 0.78%
1,189,943
– –
ORIC icon
40
Oric Pharmaceuticals
ORIC
$1.15B
$10.5M 0.56%
1,732,571
– –
CGEM icon
41
Cullinan Oncology
CGEM
$1.01B
$9.72M 0.52%
1,074,082
– –
NRIX icon
42
Nurix Therapeutics
NRIX
$2.41B
$9.63M 0.51%
1,224,892
– –
ABOS icon
43
Acumen Pharmaceuticals
ABOS
$155M
$9.16M 0.49%
+2,206,983
New +$13.6M
ZNTL icon
44
Zentalis Pharmaceuticals
ZNTL
$337M
$9.03M 0.48%
450,000
– –
ASND icon
45
Ascendis Pharma A/S
ASND
$16B
$8.9M 0.47%
95,000
– –
ELVN icon
46
Enliven Therapeutics
ELVN
$3.92B
$8.83M 0.47%
646,058
-64,586
-9% -$1.09M
PRLD icon
47
Prelude Therapeutics
PRLD
$366M
$7.71M 0.41%
2,495,018
– –
RNAM
48
DELISTED
Avidity Biosciences
RNAM
$7.15M 0.38%
1,121,327
– –
GERN icon
49
Geron
GERN
$828M
$6.36M 0.34%
3,000,000
– –
GOSS icon
50
Gossamer Bio
GOSS
$82.9M
$5.41M 0.29%
6,497,700
+3,160,772
+95% +$3.64M
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Boxer Capital held 84 positions worth $1.88B, down 13% from $2.16B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital withdrew a net $105M in Q3 2023, closing 11 positions and reducing 10 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in State Street SPDR S&P Biotech ETF worth $36.5M.

  • Boxer Capital's largest Q3 2023 buy was State Street SPDR S&P Biotech ETF: 500,000 shares worth $36.5M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $42.9M increase.
  • Boxer Capital's biggest Q3 2023 reduction was Black Diamond Therapeutics, cutting an estimated $5.56M.
  • Boxer Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $146M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.88B portfolio in Q3 2023.
  • Boxer Capital opened 5 new positions and closed 11 in Q3 2023.
  • Boxer Capital's portfolio value fell 13% quarter-over-quarter to $1.88B.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.